HRT Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

HRT Financial’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$366K	Buy	+232,264	New	+$392K	﹤0.01%	2734
2025 Q3	–	Sell	-280,077	Closed	-$254K	–	3303
2025 Q2	$254K	Buy	280,077 +71,159	+34%	+$42.2K	﹤0.01%	1946
2025 Q1	$94K	Buy	+208,918	New	+$123K	﹤0.01%	2156
2024 Q1	–	Sell	-35,923	Closed	-$39K	–	2734
2023 Q4	$39K	Buy	+35,923	New	+$39.4K	﹤0.01%	1977
2023 Q3	–	Sell	-744,628	Closed	-$1.05M	–	2786
2023 Q2	$1.05M	Buy	744,628 +495,248	+199%	+$684K	0.01%	925
2023 Q1	$374K	Buy	249,380 +229,171	+1,134%	+$320K	﹤0.01%	1579
2022 Q4	$23K	Buy	+20,209	New	+$25.5K	﹤0.01%	2168
2022 Q1	–	Sell	-135,074	Closed	-$330K	–	3498
2021 Q4	$330K	Buy	+135,074	New	+$316K	﹤0.01%	2206
2021 Q2	–	Sell	-289,018	Closed	-$679K	–	3207
2021 Q1	$679K	Buy	+289,018	New	+$694K	0.01%	1549

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial's LCTX Position: Q1 2026 in Review

HRT Financial opened a new position in Lineage Cell Therapeutics (LCTX) in Q1 2026: 232,264 shares worth $366K. The stake represents ﹤0.01% of the portfolio and ranks #2734 among its holdings. This is a return to the name: HRT Financial previously reported a position in LCTX as recently as Q2 2025.

HRT Financial first reported a position in LCTX in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.05M in Q2 2023. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

HRT Financial held 232,264 shares of Lineage Cell Therapeutics worth $366K as of Q1 2026.
Lineage Cell Therapeutics was a new HRT Financial position in Q1 2026.
Lineage Cell Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2734 holding.
HRT Financial first reported a position in Lineage Cell Therapeutics in Q1 2021 and has held it in 9 quarters since.
HRT Financial's Lineage Cell Therapeutics position peaked at $1.05M in Q2 2023.
130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.